



RNS Number : 2011A

Integrated Diagnostics Holdings PLC

18 January 2024

IDH appoints Group CFO, VP and Board Member

18 January 2024

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading clinical laboratory, and one of the largest diagnostic players in the Middle East and Africa, with operations in Jordan, Nigeria, Sudan, and Saudi Arabia, announces the appointment of Sherif El Zeiny as Board Member, President and Group Chief Financial Officer, effective 18 January 2024. El Zeiny is a seasoned and certified Director and Executive Partner, boasting over three decades of experience in financial management, business leadership, and corporate strategy. Previously, El Zeiny served as Vice President and Group Chief Financial Officer at Elsewedy Electric.

Commenting on El Zeiny's appointment, Dr. Hend El Sherbini, Group Chief Executive Officer, said: "On behalf of IDH's Board of Directors and management team, I am excited to welcome Sherif on board as Board Member, President and Group CFO. Along with the entire IDH team, I will prioritize ensuring a smooth and efficient transition as Sherif takes on his role and the Group focuses on expanding our operations, growing our top-line, and improving our margins across all geographies. I am confident that the extensive experience and unique skill set that Sherif brings with him will prove instrumental to our continued financial success moving forward."

Sherif El Zeiny, Group Chief Financial Officer, added: "I am thrilled to join IDH in such a pivotal time in its history. I am particularly excited about the Company's new venture into Saudi Arabia, which will inevitably serve to widen its market base and cement its position as a regional leader in the diagnostics field. With a firm belief that financial growth is the bedrock of any successful business, I look forward to optimizing our resources, making smart investments, and driving responsible growth under the umbrella of strong corporate governance and digital transformation to usher in another era of success for IDH and its shareholders."

-Ends-

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan, and soon launching in Saudi Arabia. The Group's brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar in Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3,000 diagnostic tests. From its base of 552 branches as of 31 December 2022, IDH served over 8.7 million patients and performs more than 32.7 million tests in 2022. IDH will continue to add laboratories through a Hub, Spoke and Spike business model which provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on demographic, healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a public limited company since its incorporation in 2015 with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 and a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.

Contact

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | tarek.yehia@idhcorp.com

LEI: 2138007JN9NUWKKTS790

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOASFFFMAELSESF